

DAFTAR PUSTAKA

- Akkız, H., Gieseler, R. K., & Canbay, A. (2024). Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells. *International Journal of Molecular Sciences*, 25(14), Article 14. <https://doi.org/10.3390/ijms25147873>
- Alhomrani, M., Correia, J., Zavou, M., Leaw, B., Kuk, N., Xu, R., Saad, M. I., Hodge, A., Greening, D. W., Lim, R., & Sievert, W. (2017). The Human Amnion Epithelial Cell Secretome Decreases Hepatic Fibrosis in Mice with Chronic Liver Fibrosis. *Frontiers in Pharmacology*, 8, 748. <https://doi.org/10.3389/fphar.2017.00748>
- An, S. Y., Jang, Y. J., Lim, H.-J., Han, J., Lee, J., Lee, G., Park, J. Y., Park, S.-Y., Kim, J. H., Do, B.-R., Han, C., Park, H.-K., Kim, O.-H., Song, M. J., Kim, S.-J., & Kim, J.-H. (2017). Milk Fat Globule-EGF Factor 8, Secreted by Mesenchymal Stem Cells, Protects Against Liver Fibrosis in Mice. *Gastroenterology*, 152(5), 1174–1186. <https://doi.org/10.1053/j.gastro.2016.12.003>
- An, S. Y., Petrescu, A. D., & DeMorrow, S. (2021). Targeting Certain Interleukins as Novel Treatment Options for Liver Fibrosis. *Frontiers in Pharmacology*, 12, 645703. <https://doi.org/10.3389/fphar.2021.645703>
- Antala, S., & Taylor, S. A. (2022). Biliary Atresia in Children: Update on disease mechanism, therapies, and patient outcomes. *Clinics in Liver Disease*, 26(3), 341–354. <https://doi.org/10.1016/j.cld.2022.03.001>
- Apriliana, S. (2024). *Pengaruh Pemberian Sekretom Hyp-UCMSC Terhadap Ekspresi mRNA HIF-1 α dan VEGF Hati Dalam Proses Angiogenesis Hewan Model Atresia Bilier*. Universitas Gadjah Mada.
- Arjmand, A., Tsiouras, M. G., Tzallas, A. T., Forlano, R., Manousou, P., & Giannakeas, N. (2020). Quantification of Liver Fibrosis—A Comparative Study. *Applied Sciences*, 10(2), Article 2. <https://doi.org/10.3390/app10020447>
- Asai, A., Miethke, A., & Bezerra, J. A. (2015). Pathogenesis of biliary atresia: Defining biology to understand clinical phenotypes. *Nature Reviews. Gastroenterology & Hepatology*, 12(6), 342–352. <https://doi.org/10.1038/nrgastro.2015.74>
- Bertolini, A., Fiorotto, R., & Strazzabosco, M. (2022). Bile acids and their receptors: Modulators and therapeutic targets in liver inflammation. *Seminars in Immunopathology*, 44(4), 547–564. <https://doi.org/10.1007/s00281-022-00935-7>
- Cao, Yan, Ji, Chenbo, & Lu, Ling. (2020). Mesenchymal stem cell therapy for liver fibrosis/cirrhosis. *Ann Transl Med*, 8(8), 1–13. <https://doi.org/10.21037/atm.2020.02.119>
- Chen, J., & Zhang, S. (2023). The Role of Inflammation in Cholestatic Liver Injury. *Journal of Inflammation Research*, Volume 16, 4527–4540. <https://doi.org/10.2147/JIR.S430730>
- Chen, Y., Zhou, J., Xu, S., & Nie, J. (2023). Role of Interleukin-6 Family Cytokines in Organ Fibrosis. *Kidney Diseases*, 9(4), 239–253. <https://doi.org/10.1159/000530288>
- Choudhary, A., & Bhagat, S. (2023). A Study on Serum IL-6 Levels in Patients with Liver Cirrhosis of Any Cause and its Correlation with Child Pugh Score in Assessing the Disease Severity. *International Journal of Research and Review*, 10(8), 22–29. <https://doi.org/10.52403/ijrr.20230804>
- Courtoy, G. E., Leclercq, I., Froidure, A., Schiano, G., Morelle, J., Devuyst, O., Huaux, F., & Bouzin, C. (2020). Digital Image Analysis of Picrosirius Red Staining: A Robust Method for Multi-Organ Fibrosis Quantification and Characterization. *Biomolecules*, 10(11), Article 11. <https://doi.org/10.3390/biom10111585>

- Cuadra, B., Silva, V., Huang, Y.-L., Diaz, Y., Rivas, C., Molina, C., Simon, V., Bono, M. R., Morales, B., Roseblatt, M., Silva, S., Acuña, R., Ezquer, F., & Ezquer, M. (2024). The Immunoregulatory and Regenerative Potential of Activated Human Stem Cell Secretome Mitigates Acute-on-Chronic Liver Failure in a Rat Model. *International Journal of Molecular Sciences*, 25(4), Article 4. <https://doi.org/10.3390/ijms25042073>
- Dong, L., Pu, Y., Chen, X., Qi, X., Zhang, L., Xu, L., Li, W., Ma, Y., Zhou, S., Zhu, J., Li, Y., Wang, X., & Su, C. (2020). hUCMSC-extracellular vesicles downregulated hepatic stellate cell activation and reduced liver injury in S. japonicum-infected mice. *Stem Cell Research & Therapy*, 11, 21. <https://doi.org/10.1186/s13287-019-1539-8>
- Driscoll, J. (2019). The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease. *J Gastroenterol*.
- Ellis, S., Lin, E. J., & Tartar, D. (2018). Immunology of Wound Healing. *Current Dermatology Reports*, 7(4), 350–358. <https://doi.org/10.1007/s13671-018-0234-9>
- Fabris, L., Spirli, C., Cadamuro, M., Fiorotto, R., & Strazzabosco, M. (2017). Emerging concepts in biliary repair and fibrosis. *American Journal of Physiology - Gastrointestinal and Liver Physiology*, 313(2), G102–G116. <https://doi.org/10.1152/ajpgi.00452.2016>
- Ferreira, J. R., Teixeira, G. Q., Santos, S. G., Barbosa, M. A., Almeida-Porada, G., & Gonçalves, R. M. (2018). Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning. *Frontiers in Immunology*, 9, 2837. <https://doi.org/10.3389/fimmu.2018.02837>
- Gabay, C. (2006). Interleukin-6 and chronic inflammation. *Arthritis Research & Therapy*, 8(Suppl 2), S3. <https://doi.org/10.1186/ar1917>
- Gallego-Durán, R., Montero-Vallejo, R., Maya-Miles, D., Lucena, A., Martin, F., Ampuero, J., & Romero-Gómez, M. (2021). Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. *Frontiers in Immunology*, 12, 667354. <https://doi.org/10.3389/fimmu.2021.667354>
- Garrido, M., Escobar, C., Zamora, C., Rejas, C., Varas, J., Párraga, M., San Martín, S., & Montedónico, S. (2017). Bile duct ligation in young rats: A revisited animal model for biliary atresia. *European Journal of Histochemistry*, 61(3). <https://doi.org/10.4081/ejh.2017.2803>
- Geervliet, E., & Bansal, R. (2020). Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. *Cells*, 9(5), 1212. <https://doi.org/10.3390/cells9051212>
- George, J., Tsuchishima, M., & Tsutsumi, M. (2019). Molecular mechanisms in the pathogenesis of N-nitrosodimethylamine induced hepatic fibrosis. *Cell Death & Disease*, 10(1), 1–9. <https://doi.org/10.1038/s41419-018-1272-8>
- Gijbels, E., Pieters, A., De Muynck, K., Vinken, M., & Devisscher, L. (2021). Rodent models of cholestatic liver disease: A practical guide for translational research. *Liver International*, 41(4), 656–682. <https://doi.org/10.1111/liv.14800>
- González-González, A., García-Sánchez, D., Dotta, M., Rodríguez-Rey, J. C., & Pérez-Campo, F. M. (2020). Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. *World Journal of Stem Cells*, 12(12), 1529–1552. <https://doi.org/10.4252/wjsc.v12.i12.1529>
- Han, J. H., Kim, O.-H., Lee, S. C., Kim, K.-H., Park, J. H., Lee, J. I., Lee, K. H., Hong, H.-E., Seo, H., Choi, H. J., Ju, J. H., & Kim, S.-J. (2019). A Novel Hepatic Anti-Fibrotic Strategy Utilizing the Secretome Released from Etanercept-Synthesizing Adipose-Derived Stem

- Cells. *International Journal of Molecular Sciences*, 20(24), 6302. <https://doi.org/10.3390/ijms20246302>
- Harrell, C., Fellabaum, C., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019). Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome. *Cells*, 8(5), 467. <https://doi.org/10.3390/cells8050467>
- Hu, C., Zhao, L., Zhang, L., Bao, Q., & Li, L. (2020). Mesenchymal stem cell-based cell-free strategies: Safe and effective treatments for liver injury. *Stem Cell Research & Therapy*, 11(1), 377. <https://doi.org/10.1186/s13287-020-01895-1>
- Huang, Y.-L., De Gregorio, C., Silva, V., Elorza, Á. A., Léniz, P., Aliaga-Tobar, V., Maracaja-Coutinho, V., Budini, M., Ezquer, F., & Ezquer, M. (2023a). Administration of Secretome Derived from Human Mesenchymal Stem Cells Induces Hepatoprotective Effects in Models of Idiosyncratic Drug-Induced Liver Injury Caused by Amiodarone or Tamoxifen. *Cells*, 12(4), 636. <https://doi.org/10.3390/cells12040636>
- Huang, Y.-L., De Gregorio, C., Silva, V., Elorza, Á. A., Léniz, P., Aliaga-Tobar, V., Maracaja-Coutinho, V., Budini, M., Ezquer, F., & Ezquer, M. (2023b). Administration of Secretome Derived from Human Mesenchymal Stem Cells Induces Hepatoprotective Effects in Models of Idiosyncratic Drug-Induced Liver Injury Caused by Amiodarone or Tamoxifen. *Cells*, 12(4), 636. <https://doi.org/10.3390/cells12040636>
- Kerola, A., Lampela, H., Lohi, J., Heikkilä, P., Mutanen, A., Hagström, J., Tervahartiala, T., Sorsa, T., Haglund, C., Jalanko, H., & Pakarinen, M. P. (2016). Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia. *The Journal of Pathology. Clinical Research*, 2(3), 187–198. <https://doi.org/10.1002/cjp2.50>
- Khanam, A., Saleeb, P. G., & Kottilil, S. (2021). Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured? *Cells*, 10(5), 1097. <https://doi.org/10.3390/cells10051097>
- Kisseleva, T., & Brenner, D. (2021). Molecular and cellular mechanisms of liver fibrosis and its regression. *Nature Reviews Gastroenterology & Hepatology*, 18(3), 151–166. <https://doi.org/10.1038/s41575-020-00372-7>
- Koyama, Y., & Brenner, D. A. (2017). Liver inflammation and fibrosis. *The Journal of Clinical Investigation*, 127(1), 55–64. <https://doi.org/10.1172/JCI88881>
- Lee, S. C., Jeong, H. J., Lee, S. K., & Kim, S.-J. (2015). Lipopolysaccharide preconditioning of adipose-derived stem cells improves liver-regenerating activity of the secretome. *Stem Cell Research & Therapy*, 6(1), 75. <https://doi.org/10.1186/s13287-015-0072-7>
- Lee, Y.-S., & Seki, E. (2023). In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations. *Cellular and Molecular Gastroenterology and Hepatology*, 16(3), 355–367. <https://doi.org/10.1016/j.jcmgh.2023.05.010>
- Lendahl, U., Lui, V. C. H., Chung, P. H. Y., & Tam, P. K. H. (2021). Biliary Atresia – emerging diagnostic and therapy opportunities. *eBioMedicine*, 74, 103689. <https://doi.org/10.1016/j.ebiom.2021.103689>
- Li, Y., Zhao, J., Yin, Y., Li, K., Zhang, C., & Zheng, Y. (2022). The Role of IL-6 in Fibrotic Diseases: Molecular and Cellular Mechanisms. *International Journal of Biological Sciences*, 18(14), 5405–5414. <https://doi.org/10.7150/ijbs.75876>
- Li, Zhang, D., Yu, Y., Wang, L., & Zhao, M. (2023). Umbilical cord-derived mesenchymal stem cell secretome promotes skin regeneration and rejuvenation: From mechanism to therapeutics. *Cell Proliferation*, 57(4), e13586. <https://doi.org/10.1111/cpr.13586>

- Liu, P., Mao, Y., Xie, Y., Wei, J., & Yao, J. (2022). Stem cells for treatment of liver fibrosis/cirrhosis: Clinical progress and therapeutic potential. *Stem Cell Research & Therapy*, 13(1), 356. <https://doi.org/10.1186/s13287-022-03041-5>
- Lo, R. C., & Kim, H. (2017). Histopathological evaluation of liver fibrosis and cirrhosis regression. *Clinical and Molecular Hepatology*, 23(4), 302–307. <https://doi.org/10.3350/cmh.2017.0078>
- Lowe, K. O., Tanase, C. E., Maghami, S., Fisher, L. E., & Ghaemmaghami, A. M. (2023). Inflammatory Network of Liver Fibrosis and How It Can Be Targeted Therapeutically. *Immuno*, 3(4), Article 4. <https://doi.org/10.3390/immuno3040023>
- Malik, A., Thanekar, U., Mourya, R., & Shivakumar, P. (2020). Recent developments in etiology and disease modeling of biliary atresia: A narrative review. *Digestive Medicine Research*, 3(0), Article 0. <https://doi.org/10.21037/dmr-20-97>
- Mannaa, F. A., & Abdel-Wahhab, K. G. (2016). Physiological potential of cytokines and liver damages. *Hepatoma Research*, 2(0), 131–143. <https://doi.org/10.20517/2394-5079.2015.58>
- Markiewski, M. M., DeAngelis, R. A., Strey, C. W., Foukas, P. G., Gerard, C., Gerard, N., Wetsel, R. A., & Lambris, J. D. (2009). The Regulation of Liver Cell Survival by Complement. *Journal of Immunology (Baltimore, Md. : 1950)*, 182(9), 5412–5418. <https://doi.org/10.4049/jimmunol.0804179>
- Mukul Vij. (2021). The Normal Liver Histology. *Pediatric Gut and Liver Journal*, 3(1), 11–12.
- Nazarie (Ignat), S.-R., Gharbia, S., Hermenean, A., Dinescu, S., & Costache, M. (2021). Regenerative Potential of Mesenchymal Stem Cells' (MSCs) Secretome for Liver Fibrosis Therapies. *International Journal of Molecular Sciences*, 22(24), 13292. <https://doi.org/10.3390/ijms222413292>
- Nomden, M., Beljaars, L., Verkade, H. J., Hulscher, J. B. F., & Olinga, P. (2020). Current Concepts of Biliary Atresia and Matrix Metalloproteinase-7: A Review of Literature. *Frontiers in Medicine*, 7, 617261. <https://doi.org/10.3389/fmed.2020.617261>
- Ortiz-Perez, A., Donnelly, B., Temple, H., Tiao, G., Bansal, R., & Mohanty, S. K. (2020). Innate Immunity and Pathogenesis of Biliary Atresia. *Frontiers in Immunology*, 11, 329. <https://doi.org/10.3389/fimmu.2020.00329>
- Osawa, Y., Hoshi, M., Yasuda, I., Saibara, T., Moriwaki, H., & Kozawa, O. (2013). Tumor Necrosis Factor- α Promotes Cholestasis-Induced Liver Fibrosis in the Mouse through Tissue Inhibitor of Metalloproteinase-1 Production in Hepatic Stellate Cells. *PLoS ONE*, 8(6), e65251. <https://doi.org/10.1371/journal.pone.0065251>
- Ozdogan, E., & Arikan, C. (2023). Liver fibrosis in children: A comprehensive review of mechanisms, diagnosis, and therapy. *Clinical and Experimental Pediatrics*, 66(3), 110–124. <https://doi.org/10.3345/cep.2022.00367>
- Pal, N., Joy, P. S., & Sergi, C. M. (2022). Biliary Atresia Animal Models: Is the Needle in a Haystack? *International Journal of Molecular Sciences*, 23(14), Article 14. <https://doi.org/10.3390/ijms23147838>
- Pinheiro, D., Dias, I., Freire, T., Thole, A. A., Stumbo, A. C., Cortez, E. A. C., de Carvalho, L., & de Carvalho, S. N. (2021). Effects of mesenchymal stem cells conditioned medium treatment in mice with cholestatic liver fibrosis. *Life Sciences*, 281(May). <https://doi.org/10.1016/j.lfs.2021.119768>
- Pinheiro, D., Dias, I., Freire, T., Thole, A. A., Stumbo, A. C., Cortez, E. A. C., De Carvalho, L., & De Carvalho, S. N. (2021). Effects of mesenchymal stem cells conditioned medium

- treatment in mice with cholestatic liver fibrosis. *Life Sciences*, 281, 119768. <https://doi.org/10.1016/j.lfs.2021.119768>
- Polyzos, S. A., Chrysavgis, L., Vachliotis, I. D., Chartampilas, E., & Cholongitas, E. (2023). Nonalcoholic fatty liver disease and hepatocellular carcinoma: Insights in epidemiology, pathogenesis, imaging, prevention and therapy. *Seminars in Cancer Biology*, 93, 20–35. <https://doi.org/10.1016/j.semcancer.2023.04.010>
- Qin, L., Liu, N., Bao, C., Yang, D., Ma, G., Yi, W., Xiao, G., & Cao, H. (2023). Mesenchymal stem cells in fibrotic diseases—The two sides of the same coin. *Acta Pharmacologica Sinica*, 44(2), 268–287. <https://doi.org/10.1038/s41401-022-00952-0>
- Qu, Y., Zhang, Q., Cai, X., Li, F., Ma, Z., Xu, M., & Lu, L. (2017). Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. *Journal of Cellular and Molecular Medicine*, 21(10), 2491–2502. <https://doi.org/10.1111/jcmm.13170>
- Ravan, A. P., Goudarzi, F., Rafieemehr, H., Bahmani, M., Rad, F., Jafari, M., & Mahmoodi, M. (2021). Human umbilical cord-mesenchymal stem cells conditioned medium attenuates CCl₄ induced chronic liver fibrosis. *Toxin Reviews*, 40(2), 238–249. <https://doi.org/10.1080/15569543.2019.1590849>
- Rich, L., & Whittaker, P. (2005). COLLAGEN AND PICROSIRIUS RED STAINING: A POLARIZED LIGHT ASSESSMENT OF FIBRILLAR HUE AND SPATIAL DISTRIBUTION. *J Morphol Sci*, 22(2), 97–104.
- Rincon, M. (2012). Interleukin-6: From an inflammatory marker to a target for inflammatory diseases. *Trends in Immunology*, 33(11), 571–577. <https://doi.org/10.1016/j.it.2012.07.003>
- Robinson, M. W., Harmon, C., & O’Farrelly, C. (2016). Liver immunology and its role in inflammation and homeostasis. *Cellular & Molecular Immunology*, 13(3), 267–276. <https://doi.org/10.1038/cmi.2016.3>
- Roeb, E. (2018). Matrix metalloproteinases and liver fibrosis (translational aspects). *Matrix Biology*, 68–69, 463–473. <https://doi.org/10.1016/j.matbio.2017.12.012>
- Sabir, U., Gu, H., & Zhang, D. (2023). Extracellular matrix turnover: Phytochemicals target and modulate the dual role of matrix metalloproteinases (MMPs) in liver fibrosis. *Phytotherapy Research*, 37(11), 4932–4962. <https://doi.org/10.1002/ptr.7959>
- Sari, M. I., Jusuf, N. K., Munir, D., Putra, A., Bisri, T., Ilyas, S., Farhat, F., Muhar, A. M., Rusda, M., & Amin, M. M. (2023). The Role of Mesenchymal Stem Cell Secretome in the Inflammatory Mediators and the Survival Rate of Rat Model of Sepsis. *Biomedicines*, 11(8), 2325. <https://doi.org/10.3390/biomedicines11082325>
- Segnani, C., Ippolito, C., Antonioli, L., Pellegrini, C., Blandizzi, C., Dolfi, A., & Bernardini, N. (2015). Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon. *PLOS ONE*, 10(12), e0144630. <https://doi.org/10.1371/journal.pone.0144630>
- Shan, L., Wang, F., Zhai, D., Meng, X., Liu, J., & Lv, X. (2023). Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis. *Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie*, 161, 114472. <https://doi.org/10.1016/j.biopha.2023.114472>
- Shen, W.-J., Chen, G., Wang, M., & Zheng, S. (2019). Liver fibrosis in biliary atresia. *World Journal of Pediatrics*, 15(2), 117–123. <https://doi.org/10.1007/s12519-018-0203-1>

- Shi, X., Zhang, K., Qi, Q., Zhou, W., Yu, F., & Zhang, Y. (2024). Human umbilical cord-derived mesenchymal stem cells attenuate hepatic stellate cells activation and liver fibrosis. *Molecular Biology Reports*, *51*(1), 734. <https://doi.org/10.1007/s11033-024-09664-6>
- Standish, R. A., Cholongitas, E., Dhillon, A., Burroughs, A. K., & Dhillon, A. P. (2006). An appraisal of the histopathological assessment of liver fibrosis. *Gut*, *55*(4), 569–578. <https://doi.org/10.1136/gut.2005.084475>
- Sugiyono. (2019). *Metodologi Penelitian Kuantitatif dan Kualitatif Dan R&D*. ALFABETA.
- Tag, C. G., Sauer-Lehnen, S., Weiskirchen, S., Borkham-Kamphorst, E., Tolba, R. H., Tacke, F., & Weiskirchen, R. (2015). Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis. *Journal of Visualized Experiments*, *96*, 52438. <https://doi.org/10.3791/52438>
- Tang, G., Nierath, W.-F., Leitner, E., Xie, W., Revskij, D., Seume, N., Zhang, X., Ehlers, L., Vollmar, B., & Zechner, D. (2024). Comparing animal well-being between bile duct ligation models. *PLOS ONE*, *19*(7), e0303786. <https://doi.org/10.1371/journal.pone.0303786>
- Tiegs, G., & Horst, A. K. (2022). TNF in the liver: Targeting a central player in inflammation. *Seminars in Immunopathology*, *44*(4), 445–459. <https://doi.org/10.1007/s00281-022-00910-2>
- Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2024). Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? *Journal of Advanced Research*. <https://doi.org/10.1016/j.jare.2024.05.004>
- Umar, Abd. K. (2023). Stem Cell's Secretome Delivery Systems. *Advanced Pharmaceutical Bulletin*, *13*(2), 244–258. <https://doi.org/10.34172/apb.2023.027>
- Vasalou, V., Kotidis, E., Tatsis, D., Boulogeorgou, K., Grivas, I., Koliakos, G., Cheva, A., Ioannidis, O., Tsingotjidou, A., & Angelopoulos, S. (2023). The Effects of Tissue Healing Factors in Wound Repair Involving Absorbable Meshes: A Narrative Review. *Journal of Clinical Medicine*, *12*(17), Article 17. <https://doi.org/10.3390/jcm12175683>
- Wang, M.-J., Zhang, H.-L., Chen, F., Guo, X.-J., Liu, Q.-G., & Hou, J. (2024). The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases. *Experimental Hematology & Oncology*, *13*(1), 62. <https://doi.org/10.1186/s40164-024-00527-1>
- Yan, R., He, Q., Liu, Y., Ye, P., Zhu, L., Shi, S., Gou, J., He, Y., Guan, T., & Zhou, G. (2023). Unpaired virtual histological staining using prior-guided generative adversarial networks. *Computerized Medical Imaging and Graphics*, *105*, 102185. <https://doi.org/10.1016/j.compmedimag.2023.102185>
- Yang, Y. M., & Seki, E. (2015). TNF α in Liver Fibrosis. *Current Pathobiology Reports*, *3*(4), 253–261. <https://doi.org/10.1007/s40139-015-0093-z>
- Yao, X., Wang, J., Zhu, J., & Rong, X. (2020). The anti-fibrotic effect of human fetal skin-derived stem cell secretome on the liver fibrosis. *Stem Cell Research and Therapy*, *11*(1), 1–10. <https://doi.org/10.1186/s13287-020-01891-5>
- Yin, F., Wang, W.-Y., & Jiang, W.-H. (2019). Human umbilical cord mesenchymal stem cells ameliorate liver fibrosis in vitro and in vivo: From biological characteristics to therapeutic mechanisms. *World Journal of Stem Cells*, *11*(8), 548–564. <https://doi.org/10.4252/wjsc.v11.i8.548>
- Yokota, S., Ono, Y., Nakao, T., Zhang, P., Michalopoulos, G. K., & Khan, Z. (2018). Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis. *Journal of Visualized Experiments: JoVE*, *133*, 56930. <https://doi.org/10.3791/56930>

- Zehra, M., Curry, J. C., Pillai, S. S., Lakhani, H. V., Edwards, C. E., & Sodhi, K. (2020). Elucidating Potential Profibrotic Mechanisms of Emerging Biomarkers for Early Prognosis of Hepatic Fibrosis. *International Journal of Molecular Sciences*, 21(13), 4737. <https://doi.org/10.3390/ijms21134737>
- Zeng, J., Fan, J., & Zhou, H. (2023). Bile acid-mediated signaling in cholestatic liver diseases. *Cell & Bioscience*, 13(1), 77. <https://doi.org/10.1186/s13578-023-01035-1>
- Zhang, D., Zhang, Y., & Sun, B. (2022). The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. *International Journal of Molecular Sciences*, 23(20), Article 20. <https://doi.org/10.3390/ijms232012572>
- Zhang, K., Chen, Y., Zheng, Z., Tang, C., Zhu, D., Xia, X., Huang, L., Du, Q., Liu, Y., & Jin, Z. (2022). Relationship between the expression levels of CD4+ T cells, IL-6, IL-8 and IL-33 in the liver of biliary atresia and postoperative cholangitis, operative age and early jaundice clearance. *Pediatric Surgery International*, 38(12), 1939–1947. <https://doi.org/10.1007/s00383-022-05258-0>
- Zhao, S., Jiang, J., Jing, Y., Liu, W., Yang, X., Hou, X., Gao, L., & Wei, L. (2020). The concentration of tumor necrosis factor- α determines its protective or damaging effect on liver injury by regulating Yap activity. *Cell Death & Disease*, 11(1), 70. <https://doi.org/10.1038/s41419-020-2264-z>
- Zhu, Y., Ge, J., Huang, C., Liu, H., & Jiang, H. (2021). Application of mesenchymal stem cell therapy for aging frailty: From mechanisms to therapeutics. *Theranostics*, 11(12), 5675–5685. <https://doi.org/10.7150/thno.46436>



UNIVERSITAS
GADJAH MADA

Pengaruh Pemberian Sekretom UC-MSC Terhadap Ekspresi mRNA IL-6 dan TNF- α , serta Indikator Fibrosis

pada Organ Hati Hewan Model Atresia Bilier

Dellarius Benefit Yubaidi, dr. Eko Purnomo, Ph.D, Subsp.D.A(K); dr. Junaedy Yunus, M.Sc, Ph.D

Universitas Gadjah Mada, 2025 | Diunduh dari <http://etd.repository.ugm.ac.id/>